Data Transformation · Biotech & Life Sciences
Data Transformation for Biotech & Life Sciences
Data warehousing, attribution modeling, and analytics pipelines that unify marketing, sales, and product telemetry. Investor relations, scientific communications, and growth marketing for biotech, pharma, medtech, and life sciences companies.
Book a 15-min strategy callThe Biotech & Life Sciences context
What data transformation means for biotech & life sciences companies
Biotech marketing in 2026 must respect SEC fair disclosure rules, FDA promotional restrictions, clinical trial blackout periods, and MLR (Medical/Legal/Regulatory) review processes. Long timelines (pre-clinical to commercial: 7-15 years) require sustained narrative investment without short-term traffic metrics as proof.
Empire325 designs and operates modern data stacks that unify marketing, sales, product, and finance telemetry into a single source of truth. From dbt transformations to attribution modeling, we ship analytics infrastructure that pays for itself in months.
Biotech & Life Sciences is a regulated sector, which materially changes how data transformation engagements have to be structured. Empire325 operates within the applicable compliance framework (U.S. Food and Drug Administration guidance, supervisory review, and documented approval workflows) rather than around it. Programs are co-designed with your compliance counsel and chief compliance officer so that creative, distribution, measurement, and reporting all survive an audit. This is materially different from generic agency engagements that treat compliance as an afterthought and produce campaigns that get retroactively pulled or restricted.
For the canonical industry framing, see U.S. Food and Drug Administration — Empire325 references that source-of-truth when building the measurement, attribution, and compliance baseline for every biotech & life sciences data transformation engagement. The methodology layer above it draws on dbt Labs and our own production patterns from prior biotech & life sciences engagements.
Capabilities
Data Transformation capabilities for biotech & life sciences clients
Why Empire325
Why Empire325 for biotech & life sciences data transformation
Empire325 biotech marketing combines IR, scientific communications, KOL engagement, and commercial-readiness marketing — built alongside your regulatory and legal counsel. Scientific accuracy under MLR review, Reg-FD-aligned investor communications.
Measured outcomes
What biotech & life sciences clients achieve
Single source of truth for revenue data
MTA models proving channel-level ROAS
Cohort + retention analytics
Compliance-ready data governance
FAQ — Data Transformation for Biotech & Life Sciences
Does Empire325 provide data transformation for biotech & life sciences companies?
Yes. Empire325 delivers data transformation specifically calibrated for biotech & life sciences companies. Empire325 biotech marketing combines IR, scientific communications, KOL engagement, and commercial-readiness marketing — built alongside your regulatory and legal counsel. Scientific accuracy under MLR review, Reg-FD-aligned investor communications.
What makes data transformation different for biotech & life sciences vs. other industries?
Biotech marketing in 2026 must respect SEC fair disclosure rules, FDA promotional restrictions, clinical trial blackout periods, and MLR (Medical/Legal/Regulatory) review processes. Long timelines (pre-clinical to commercial: 7-15 years) require sustained narrative investment without short-term traffic metrics as proof. Empire325 applies data transformation methodology with these industry-specific constraints and opportunities built in — not as an afterthought.
How much does data transformation cost for biotech & life sciences companies?
Data Transformation engagements for biotech & life sciences clients typically range from $10K–$60K monthly retainers depending on scope, team size, and market reach. Empire325 provides written scoping after a 30-minute discovery call. Most engagements deliver first measurable outcomes within 60–90 days.
Why choose Empire325 for biotech & life sciences data transformation?
Empire325 biotech marketing combines IR, scientific communications, KOL engagement, and commercial-readiness marketing — built alongside your regulatory and legal counsel. Scientific accuracy under MLR review, Reg-FD-aligned investor communications. Empire325's data transformation practice combines technical depth with biotech & life sciences-specific domain knowledge — so the work lands in your market, not just in a generic framework.
References & further reading
Sources cited on this data transformation for biotech & life sciences page
- dbt Labs — dbt Labs analytics-engineering best practices and modern-data-stack reference.
- U.S. Food and Drug Administration — FDA Center for Drug Evaluation and Research promotional-communications guidance.
- Harvard Business Review — Harvard Business Review research on industry-specific marketing strategy and ROI benchmarks.
Need data transformation for your biotech & life sciences company?
15-minute strategy call. No deck, no pitch — specific recommendations based on your context.
Book a 15-min strategy call